|
|
 |
|
Viewing report
|
|
|
|
Psoriasis - Biologics are Yet to Make Topical Treatments Obsolete
Datamonitor, March 2009, Pages: 185
Patient perception of disease severity drives treatment-seeking behavior in psoriasis. New therapeutic options targeting specific mechanisms are set to reshape severe psoriasis therapy. However, current biologics have not undermined first-line topical therapy. In addition to efficacy, reimbursement plays a crucial role in physicians prescribing decisions.
Scope
- Opinion from 180 practicing dermatologists, each treating at least 40 psoriasis patients per month
- Including data from physicians and opinion leaders across the seven major markets of the US, Japan, France, Germany, Spain, Italy and the UK
- Analysis of psoriasis population attributes, physicians prescribing decisions, therapy outcomes and treatment satisfaction
- Brand analysis of key pharmaceuticals used in psoriasis, including biologics and branded topical formulations
Highlights of this title
The low estimated diagnosis rate of 54% reflects a lack of treatment-seeking by mild sufferers. Despite nearly 10 million diagnosed patients, the market value of psoriasis is constrained by reliance on generic and non-prescription treatments in mild disease.
Biologics risk-benefit and cost-benefit ratios are coming under review. Humira (adalimumab) and Stelara (ustekinumab) stand to benefit from the withdrawal of Raptiva (efalizumab) from the EU and more stringent labeling in the US. The position of biologics in moderate to severe psoriasis is up for challenge by payers attempting to control costs.
Topical treatments are the foundation of therapy, used alone by at least 82% of mild patients. Phototherapy is a cost-effective treatment option in psoriasis unresponsive to topical therapy. Most physicians surveyed recommend phototherapy to up to 30% of patients, and payers may influence greater use of phototherapy.
Key reasons to purchase this title
- Understand how patient behavior controls the size of the psoriasis market
- Interpret physicians priorities in prescribing personalized psoriasis treatment regimens
- Assess the regional dynamics of therapy choice in psoriasis, dictated by product availability, regulation and reimbursement
Customers who bought this item also bought
Psoriasis - Biologics Impact Treatment Regimes Across The Globe
Commercial Insight: Psoriasis - Intellectual property drives growth
North American Psoriasis and Psoriatic Arthritis Markets
Psoriasis Market Forecast
U.S. Market for Psoriasis Cream and Medication 2009
Commercial and Pipeline Insight: Psoriasis - Anti-TNFs Lead Another Indication
Pipeline and Commercial Perspectives: Psoriasis and Atopic Dermatitis - Reimbursement the key as biologics and TIMs transform disease markets
Therapeutic Clinical Intelligence - Psoriasis
U.S. Emerging Psoriasis Therapeutics Markets
U.S. Market for Psoriasis Cream and Medication 2009 (Executive Summary)
US market size for psoriasis medications by prevalence of moderate-to-severe disease in 2001 forecast to 2006, with forecast patient numbers, dollar sales and operating profits for Genentech Inc's new Xanelim psoriasis drug in 2004 to 2006
Psoriasis: Opinion Leader Forum - Expert's Views and Perspectives on Diagnosis, Treatment, Product Performance and Closing the Need Gap
|
|
|
|
